Zacks Investment Research upgraded shares of Abcam PLC (NASDAQ:ABCZY) from a hold rating to a buy rating in a report released on Tuesday morning. They currently have $16.00 price objective on the stock.

According to Zacks, “Abcam PLC distributes antibodies and associated protein research tools. Its product includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. Abcam PLC is headquartered in Cambridge, the United Kingdom. “

Abcam PLC (NASDAQ:ABCZY) opened at 13.79 on Tuesday. The stock has a 50 day moving average price of $14.15 and a 200 day moving average price of $12.82. Abcam PLC has a 12 month low of $9.13 and a 12 month high of $15.22. The stock has a market capitalization of $2.81 billion and a P/E ratio of 50.33.

WARNING: “Abcam PLC (ABCZY) Raised to Buy at Zacks Investment Research” was first published by Watch List News and is the property of of Watch List News. If you are viewing this news story on another site, it was stolen and reposted in violation of international trademark & copyright law. The original version of this news story can be read at

Get a free copy of the Zacks research report on Abcam PLC (ABCZY)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Abcam PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.